Panagora Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Panagora Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$507K	Sell	34,789 -54,810	-61%	-$737K	﹤0.01%	893
2026 Q1	$1.13M	Buy	89,599 +22,609	+34%	+$303K	﹤0.01%	691
2025 Q4	$1.06M	Buy	+66,990	New	+$851K	﹤0.01%	702
2020 Q2	–	Sell	-1,114	Closed	-$57K	–	2587
2020 Q1	$57K	Buy	+1,114	New	+$59.4K	﹤0.01%	1853
2018 Q2	–	Sell	-1,458	Closed	-$118K	–	2382
2018 Q1	$118K	Buy	+1,458	New	+$112K	﹤0.01%	1815
2015 Q4	–	Sell	-648	Closed	-$23K	–	2315
2015 Q3	$23K	Buy	648 +39	+6%	+$1.68K	﹤0.01%	2118
2015 Q2	$27K	Buy	+609	New	+$23.7K	﹤0.01%	2258
2015 Q1	–	Sell	-11,613	Closed	-$591K	–	2344
2014 Q4	$591K	Buy	11,613 +9,545	+462%	+$427K	﹤0.01%	1219
2014 Q3	$82K	Sell	2,068 -160	-7%	-$6.38K	﹤0.01%	1913
2014 Q2	$96K	Sell	2,228 -297	-12%	-$11.3K	﹤0.01%	1943
2014 Q1	$101K	Buy	+2,525	New	+$91.7K	﹤0.01%	1929
2013 Q4	–	Sell	-13,546	Closed	-$310K	–	2189
2013 Q3	$310K	Sell	13,546 -9,426	-41%	-$180K	﹤0.01%	1497
2013 Q2	$407K	Buy	+22,972	New	+$448K	﹤0.01%	1386

Other funds holding ENTA

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KAM

Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Panagora Asset Management's ENTA Position: Q2 2026 in Review

Panagora Asset Management reduced its Enanta Pharmaceuticals (ENTA) stake by 61% in Q2 2026, selling an estimated $737K and leaving 34,789 shares worth $507K. The position accounts for ﹤0.01% of the portfolio, ranked #893.

Panagora Asset Management first reported a position in ENTA in Q2 2013 and has held it in 13 quarters since. The position peaked at $1.13M in Q1 2026. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

Panagora Asset Management held 34,789 shares of Enanta Pharmaceuticals worth $507K as of Q2 2026.
Panagora Asset Management sold 54,810 Enanta Pharmaceuticals shares in Q2 2026, an estimated $737K.
Enanta Pharmaceuticals made up ﹤0.01% of Panagora Asset Management's portfolio in Q2 2026, its #893 holding.
Panagora Asset Management first reported a position in Enanta Pharmaceuticals in Q2 2013 and has held it in 13 quarters since.
Panagora Asset Management's Enanta Pharmaceuticals position peaked at $1.13M in Q1 2026.
123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.